A Double-Blind, Randomised, Placebo-Controlled Trial Confirming the Efficacy of Intranasal Fentanyl Titrated to 50, 100 or 200 microg With an Open Long-Term Safety Follow-up in Cancer Patients With Breakthrough Pain.

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled Trial Confirming the Efficacy of Intranasal Fentanyl Titrated to 50, 100 or 200 microg With an Open Long-Term Safety Follow-up in Cancer Patients With Breakthrough Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Oct 2012 Planned number of patients changed from 100 to 200.
    • 02 Feb 2010 Actual end date changed from Jan 2008 to Mar 2008 as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top